Breaking News, Collaborations & Alliances

NorthStar, BWXT Sign Master Services Agreement Supporting Actinium-225 Production

Actinium-225 is a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.

Author Image

By: Charlie Sternberg

Associate Editor

NorthStar Medical Radioisotopes LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc., have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues. Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters